Novavax Total Current Assets vs Deferred Long Term Liab Analysis

NVAX Stock

USD 4.93 0.22 4.67%

Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Total Current Assets and its Deferred Long Term Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Total Current Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Novavax's Total Current Assets and Deferred Long Term Liab is -0.21. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Total Current Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Novavax are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Current Assets i.e., Novavax's Total Current Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

-0.21

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).

Novavax fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.78	0.94	-0.56	0.87	-0.87	-0.91	0.93	0.94	0.9	0.94	0.94	0.93	0.8	0.94	0.96	0.86	0.99	0.88	0.78	-0.46	0.71	-0.41	0.67	-0.37	0.33
Other Current Liab	0.78		0.9	-0.89	0.91	-0.66	-0.9	0.93	0.72	0.88	0.75	0.68	0.84	0.55	0.85	0.9	0.91	0.7	0.55	0.66	-0.35	0.53	-0.32	0.34	-0.26	0.02
Total Current Liabilities	0.94	0.9		-0.75	0.86	-0.88	-0.92	0.96	0.94	0.87	0.93	0.92	0.88	0.83	0.89	0.98	0.86	0.92	0.76	0.67	-0.4	0.68	-0.41	0.55	-0.36	0.21
Total Stockholder Equity	-0.56	-0.89	-0.75		-0.74	0.4	0.79	-0.72	-0.53	-0.71	-0.63	-0.45	-0.69	-0.4	-0.69	-0.76	-0.75	-0.48	-0.4	-0.62	0.35	-0.56	0.21	-0.06	0.15	-0.19
Property Plant And Equipment Net	0.87	0.91	0.86	-0.74		-0.62	-0.96	0.91	0.7	0.99	0.77	0.69	0.97	0.46	0.96	0.92	1.0	0.78	0.74	0.87	-0.43	0.56	-0.36	0.46	-0.3	0.14
Net Debt	-0.87	-0.66	-0.88	0.4	-0.62		0.67	-0.82	-0.94	-0.65	-0.87	-0.94	-0.67	-0.9	-0.68	-0.8	-0.61	-0.91	-0.74	-0.38	0.22	-0.45	0.47	-0.6	0.46	-0.03
Retained Earnings	-0.91	-0.9	-0.92	0.79	-0.96	0.67		-0.93	-0.8	-0.97	-0.86	-0.77	-0.98	-0.6	-0.99	-0.97	-0.96	-0.85	-0.77	-0.89	0.5	-0.72	0.34	-0.48	0.28	-0.33
Accounts Payable	0.93	0.93	0.96	-0.72	0.91	-0.82	-0.93		0.89	0.91	0.83	0.88	0.9	0.74	0.92	0.96	0.91	0.89	0.68	0.7	-0.41	0.67	-0.4	0.65	-0.36	0.17
Cash	0.94	0.72	0.94	-0.53	0.7	-0.94	-0.8	0.89		0.73	0.92	0.99	0.77	0.95	0.8	0.9	0.69	0.97	0.76	0.57	-0.4	0.73	-0.41	0.71	-0.39	0.34
Non Current Assets Total	0.9	0.88	0.87	-0.71	0.99	-0.65	-0.97	0.91	0.73		0.81	0.72	0.99	0.49	0.98	0.93	0.99	0.82	0.79	0.89	-0.44	0.59	-0.35	0.47	-0.29	0.19
Non Currrent Assets Other	0.94	0.75	0.93	-0.63	0.77	-0.87	-0.86	0.83	0.92	0.81		0.9	0.85	0.82	0.86	0.94	0.77	0.94	0.9	0.71	-0.43	0.66	-0.44	0.45	-0.41	0.35
Cash And Short Term Investments	0.94	0.68	0.92	-0.45	0.69	-0.94	-0.77	0.88	0.99	0.72	0.9		0.76	0.94	0.79	0.88	0.67	0.98	0.77	0.55	-0.41	0.7	-0.4	0.74	-0.38	0.32
Common Stock Shares Outstanding	0.93	0.84	0.88	-0.69	0.97	-0.67	-0.98	0.9	0.77	0.99	0.85	0.76		0.55	0.99	0.95	0.97	0.86	0.84	0.92	-0.48	0.65	-0.39	0.5	-0.34	0.29
Other Current Assets	0.8	0.55	0.83	-0.4	0.46	-0.9	-0.6	0.74	0.95	0.49	0.82	0.94	0.55		0.59	0.75	0.45	0.87	0.61	0.33	-0.32	0.68	-0.36	0.67	-0.36	0.34
Other Stockholder Equity	0.94	0.85	0.89	-0.69	0.96	-0.68	-0.99	0.92	0.8	0.98	0.86	0.79	0.99	0.59		0.96	0.96	0.87	0.82	0.91	-0.5	0.7	-0.34	0.54	-0.28	0.33
Total Liab	0.96	0.9	0.98	-0.76	0.92	-0.8	-0.97	0.96	0.9	0.93	0.94	0.88	0.95	0.75	0.96		0.92	0.92	0.82	0.81	-0.47	0.73	-0.39	0.54	-0.34	0.32
Property Plant And Equipment Gross	0.86	0.91	0.86	-0.75	1.0	-0.61	-0.96	0.91	0.69	0.99	0.77	0.67	0.97	0.45	0.96	0.92		0.77	0.73	0.87	-0.42	0.55	-0.36	0.43	-0.29	0.13
Total Current Assets	0.99	0.7	0.92	-0.48	0.78	-0.91	-0.85	0.89	0.97	0.82	0.94	0.98	0.86	0.87	0.87	0.92	0.77		0.87	0.7	-0.45	0.71	-0.41	0.72	-0.38	0.36
Net Receivables	0.88	0.55	0.76	-0.4	0.74	-0.74	-0.77	0.68	0.76	0.79	0.9	0.77	0.84	0.61	0.82	0.82	0.73	0.87		0.77	-0.38	0.49	-0.46	0.41	-0.43	0.31
Non Current Liabilities Total	0.78	0.66	0.67	-0.62	0.87	-0.38	-0.89	0.7	0.57	0.89	0.71	0.55	0.92	0.33	0.91	0.81	0.87	0.7	0.77		-0.55	0.7	-0.24	0.39	-0.18	0.52
Intangible Assets	-0.46	-0.35	-0.4	0.35	-0.43	0.22	0.5	-0.41	-0.4	-0.44	-0.43	-0.41	-0.48	-0.32	-0.5	-0.47	-0.42	-0.45	-0.38	-0.55		-0.59	0.11	-0.32	0.08	-0.53
Short Long Term Debt Total	0.71	0.53	0.68	-0.56	0.56	-0.45	-0.72	0.67	0.73	0.59	0.66	0.7	0.65	0.68	0.7	0.73	0.55	0.71	0.49	0.7	-0.59		-0.12	0.65	-0.1	0.82
Common Stock Total Equity	-0.41	-0.32	-0.41	0.21	-0.36	0.47	0.34	-0.4	-0.41	-0.35	-0.44	-0.4	-0.39	-0.36	-0.34	-0.39	-0.36	-0.41	-0.46	-0.24	0.11	-0.12		-0.34	0.99	0.09
Short Term Debt	0.67	0.34	0.55	-0.06	0.46	-0.6	-0.48	0.65	0.71	0.47	0.45	0.74	0.5	0.67	0.54	0.54	0.43	0.72	0.41	0.39	-0.32	0.65	-0.34		-0.34	0.37
Common Stock	-0.37	-0.26	-0.36	0.15	-0.3	0.46	0.28	-0.36	-0.39	-0.29	-0.41	-0.38	-0.34	-0.36	-0.28	-0.34	-0.29	-0.38	-0.43	-0.18	0.08	-0.1	0.99	-0.34		0.09
Long Term Debt	0.33	0.02	0.21	-0.19	0.14	-0.03	-0.33	0.17	0.34	0.19	0.35	0.32	0.29	0.34	0.33	0.32	0.13	0.36	0.31	0.52	-0.53	0.82	0.09	0.37	0.09

Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Liab	19.9M	(327.6M)	709.8M	1.5B	1.2B	1.3B
Total Current Liabilities	25.8M	322.0M	2.4B	2.5B	1.6B	1.7B
Total Stockholder Equity	(186.0M)	627.2M	(351.7M)	(634.1M)	(716.9M)	(681.1M)
Property Plant And Equipment Net	11.4M	180.0M	228.7M	400.5M	491.0M	515.5M
Net Debt	243.1M	(231.4M)	(1.1B)	(787.1M)	(298.3M)	(283.4M)
Retained Earnings	(1.4B)	(1.9B)	(3.6B)	(4.3B)	(4.8B)	(4.6B)
Accounts Payable	2.9M	54.3M	127.1M	216.5M	132.6M	139.2M
Cash	78.8M	553.4M	1.5B	1.3B	578.9M	607.9M
Non Current Assets Total	75.7M	334.3M	421.6M	555.3M	711.5M	747.0M
Non Currrent Assets Other	7.5M	13.2M	56.7M	28.5M	30.3M	31.8M
Cash And Short Term Investments	78.8M	711.0M	1.5B	1.3B	578.9M	607.9M
Common Stock Shares Outstanding	24.1M	57.6M	74.4M	78.2M	100.8M	105.8M
Liabilities And Stockholders Equity	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Assets	93.9M	441.8M	2.1B	1.7B	226.0M	191.7M
Other Stockholder Equity	1.3B	2.5B	3.3B	3.6B	4.1B	4.3B
Total Liab	359.0M	955.3M	2.9B	2.9B	2.6B	2.7B
Property Plant And Equipment Gross	11.4M	180.0M	258.6M	447.8M	566.0M	594.3M
Total Current Assets	97.2M	1.2B	2.2B	1.7B	1.1B	1.2B
Accumulated Other Comprehensive Income	(12.5M)	7.0M	(1.4M)	(6.4M)	2.7M	2.9M
Net Receivables	7.5M	262.0M	455.0M	82.4M	297.2M	312.1M
Non Current Liabilities Total	333.2M	633.2M	538.1M	432.8M	937.1M	984.0M
Intangible Assets	6.5M	5.6M	5.7M	4.8M	4.3M	4.1M
Short Long Term Debt Total	321.9M	322.0M	454.0M	549.8M	280.6M	294.7M
Common Stock Total Equity	3.8M	324K	714K	764K	878.6K	1.3M
Short Term Debt	1.3M	322.0M	130.5M	352.1M	28.1M	43.9M
Common Stock	324K	714K	764K	868K	1.4M	1.3M
Long Term Debt	320.6M	322.0M	323.5M	166.5M	168.0M	114.6M
Inventory	(83.0M)	(166.7M)	(2.0B)	36.7M	41.7M	43.8M
Property Plant Equipment	11.4M	180.0M	228.7M	400.5M	460.6M	483.6M
Other Liab	2.6M	3.4M	175.5M	185.0M	212.8M	223.4M
Current Deferred Revenue	1.7M	273.2M	1.4B	370.1M	241.3M	140.2M
Other Assets	1.1M	5.4M	16.6M	28.5M	32.7M	34.4M
Good Will	51.2M	135.4M	131.5M	126.3M	127.5M	133.8M
Net Tangible Assets	(242.8M)	486.1M	(487.9M)	(760.4M)	(684.4M)	(650.1M)
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.9B)	(3.6B)	(3.3B)	(3.1B)
Long Term Debt Total	319.2M	320.6M	322.0M	323.5M	372.0M	234.9M
Capital Surpluse	1.1B	1.3B	2.5B	3.4B	3.9B	4.0B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:

How To Invest In Novavax

Details

Is Novavax Stock a good investment?

Details

What is Novavax's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Transaction History View history of all your transactions and understand their impact on performance
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing

Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.41)

Revenue Per Share

9.762

Quarterly Revenue Growth

(0.18)

Return On Assets

(0.17)

Return On Equity

(8.98)

The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novavax Total Current Assets vs Deferred Long Term Liab Analysis

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Total Current Assets

Deferred Long Term Liab

Novavax fundamental ratios Correlations

Novavax Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novavax fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novavax Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Common Stock Shares Outstanding	+ 0.99	Non Current Assets Total
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net